Physician profile
Asif Ali
NPI 1881621993
$410,523.67
in general payments reported to CMS, 2019-2025
63 companies · $20K in 2025
The $20K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $43K · 2021: $161K · 2022: $56K · 2023: $46K · 2024: $40K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Food and Beverage: $11K · Travel and Lodging: $4,093 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,345.00 |
| Food and Beverage | $10,850.60 |
| Travel and Lodging | $4,092.85 |
| Education | $102.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $143,053.01 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $118,122.51 | 2019-2025 | Jardiance, Mounjaro |
| Preventric Diagnostics, INC. | $78,083.33 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50,897.95 | 2019-2025 | Lifevest |
| Abbott Laboratories | $5,207.96 | 2019-2024 | Octrode, Coroflow, Confirm Rx |
| Novartis Pharmaceuticals Corporation | $2,550.92 | 2019-2025 | |
| Cleerly, INC. | $890.59 | 2023-2025 | Cleerly Labs, Cleerly Ischemia |
| Janssen Pharmaceuticals, INC | $871.75 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $834.12 | 2019-2025 | Watchman Flx, Bodyguardian, Watchman Access System |
| Amgen INC. | $821.63 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $564.75 | 2020-2025 | Farxiga, Lokelma |
| Ablative Solutions, INC. | $551.56 | 2019-2022 | |
| Pfizer INC. | $537.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $498.44 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Arbor Pharmaceuticals, INC. | $417.20 | 2019-2022 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $411.57 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Novo Nordisk INC | $407.59 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic Vascular, INC. | $373.80 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $363.91 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $346.21 | 2019-2025 | Camzyos |
| Bardy Diagnostics, INC. | $334.93 | 2019-2021 | |
| Astellas Pharma US INC | $329.99 | 2019-2024 | Veozah |
| Baxter Healthcare | $319.94 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Esperion Therapeutics, INC. | $280.07 | 2020-2025 | Nexletol |
| Akcea Therapeutics, INC. | $250.03 | 2019-2021 | |
| Heartflow, INC. | $241.34 | 2024 | |
| Corcept Therapeutics | $234.07 | 2025 | Korlym |
| Abiomed | $231.07 | 2019-2021 | |
| Lundbeck LLC | $224.08 | 2019-2021 | |
| Acarix USA INC. | $217.58 | 2024-2025 | Cadscor System |
| Philips North America LLC | $182.12 | 2019-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Endologix LLC | $182.03 | 2019 | |
| Impulse Dynamics (USA) INC. | $171.39 | 2022 | |
| Amarin Pharma, INC. | $163.73 | 2019-2022 | |
| Biotronik INC. | $146.60 | 2020-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $121.40 | 2022-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $121.22 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $112.71 | 2019 | |
| Medtronic, INC. | $96.52 | 2023 | Linq II |
| Azurity Pharmaceuticals, INC. | $78.64 | 2024 | Edarbi |
| Idorsia Pharmaceuticals US INC | $70.41 | 2024 | Tryvio |
| Surmodics, INC. | $49.52 | 2022 | |
| Scpharmaceuticals INC. | $49.02 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $47.20 | 2024 | Arcalyst |
| Veryan Medical Incorporated | $41.90 | 2022 | |
| Preventice Services, LLC | $40.17 | 2020-2021 | |
| Gilead Sciences, INC. | $35.93 | 2019 | |
| Relievant Medsystems, INC. | $33.80 | 2023 | Intracept |
| Bolton Medical INC | $30.42 | 2023 | Treo Abdominal Stent-Graft System |
| Innovation Technologies INC | $29.00 | 2023 | Irrisept |
| Kestra Medical Technology Services, INC. | $25.25 | 2024 | Assure Wcd |
| Irhythm Technologies, INC. | $25.19 | 2023 | Zio Xt Patch |
| Nevro Corp. | $24.22 | 2023 | Senza |
| Glaxosmithkline, LLC. | $23.38 | 2024 | Arexvy, Trelegy Ellipta |
| Tactile Systems Technology INC | $21.61 | 2025 | Nimbl, Flexitouch Plus |
| Althera Pharmaceuticals LLC | $21.40 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $20.54 | 2022 | |
| Agepha Pharma Fz LLC | $18.23 | 2024 | Lodoco |
| Myocardial Solutions, INC. | $15.06 | 2021 | |
| Cardiva Medical, INC. | $14.83 | 2020 | |
| Cashflow Solutions, LLC | $14.14 | 2022 | |
| Edwards Lifesciences Corporation | $14.02 | 2022 | |
| Genzyme Corporation | $12.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$119.49 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.